Lineage Cell Therapeutics (LCTX) Gross Margin (2011 - 2026)

Lineage Cell Therapeutics' Gross Margin history runs 16 years deep, the most recent figure standing at 100.0% for Q1 2026.

• On a quarterly basis, Gross Margin rose 240.0% year-over-year to 100.0% in Q1 2026; TTM through Mar 2026 was 99.26%, a 210.0% increase from a year earlier, with the FY2025 full-year figure at 99.0%, up 251.0% from the prior year.
• Gross Margin advanced to 100.0% in Q1 2026 per LCTX's latest filing, from 99.0% in the prior quarter.
• Across five years, Gross Margin topped out at 100.0% in Q1 2026 and bottomed at 86.44% in Q3 2023.
• The 5-year median for Gross Margin is 96.06% (2023), against an average of 95.46%.
• Across the five-year window, Gross Margin surged 9275 bps in 2022 and plunged 693 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 94.67% in 2022, then fell by 7 bps to 87.74% in 2023, then grew by 8 bps to 94.63% in 2024, then increased by 5 bps to 99.0% in 2025, then climbed by 1 bps to 100.0% in 2026.
• Per Business Quant, the three latest LCTX Gross Margin figures stand at 100.0% (Q1 2026), 99.0% (Q4 2025), and 99.86% (Q3 2025).